CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intraturnoral CD4+CD25- T cells

被引:163
作者
Yang, Zhi-Zhang [1 ]
Novak, Anne J. [1 ]
Ziesmer, Steven C. [1 ]
Witzig, Thomas E. [1 ]
Ansell, Stephen M. [1 ]
机构
[1] Mayo Clin, Coll Med, Div Hematol & Internal Med, Rochester, MN 55905 USA
关键词
D O I
10.1182/blood-2007-03-082578
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Foxp3 expression was initially thought to be restricted to the CD4(+)CD25(+) regulatory T-cell population. However, recent studies suggest that forkhead box P3 (Foxp3) is expressed in CD4(+)CD25(-) T cells in aged mice. In the present study in B-cell non-Hodgkin lymphoma (NHL), we found that a subset of intratumoral but not peripheral blood CD4+CD25- T cells, comprising about 15% of intratumoral CD4(+) T cells, express Foxp3 and are capable of suppressing the proliferation of autologous infiltrating CD8(+) T cells. In vitro activation with OKT3/anti-CD28 antibody (Ab) or dendritic cells (DCs) induced Foxp3 expression in a subset of these CD4(+)CD25(-)Foxp3(-) T cells. We found that the presence of lymphoma B cells during activation augmented activation-induced Foxp3 expression in CD4(+)CD25(-) T cells. We also found that CD70(+) lymphoma B cells significantly contributed to the activation-induced Foxp3 expression in intratumoral CD4(+)CD25(-) T cells. Furthermore, the blockade of CD27-CD70 interaction by anti-CD70 Ab abrogated lymphoma B-cell-mediated induction of Foxp3 expression in intratumoral CD4(+)CD25(-) T cells. Taken together, these studies reveal a novel role for NHL B cells in the development of intratumoral regulatory T cells.
引用
收藏
页码:2537 / 2544
页数:8
相关论文
共 47 条
[1]   The role of 2 FOXP3 isoforms in the generation of human CD4+ Tregs [J].
Allan, SE ;
Passerini, L ;
Bacchetta, R ;
Crellin, N ;
Dai, MY ;
Orban, PC ;
Ziegler, SF ;
Roncarolo, MG ;
Levings, MK .
JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (11) :3276-3284
[2]   CD8+T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells [J].
Antony, PA ;
Piccirillo, CA ;
Akpinarli, A ;
Finkelstein, SE ;
Speiss, PJ ;
Surman, DR ;
Palmer, DC ;
Chan, CC ;
Klebanoff, CA ;
Overwijk, WW ;
Rosenberg, SA ;
Restifo, NP .
JOURNAL OF IMMUNOLOGY, 2005, 174 (05) :2591-2601
[3]   Constitutive CD27/CD70 interaction induces expansion of effector-type T cells and results in IFNγ-mediated B cell depletion [J].
Arens, R ;
Tesselaar, K ;
Baars, PA ;
van Schijndel, GMW ;
Hendriks, J ;
Pals, ST ;
Krimpenfort, P ;
Borst, J ;
van Oers, MHJ ;
van Lier, RAW .
IMMUNITY, 2001, 15 (05) :801-812
[4]   CD4+CD25high regulatory cells in human peripheral blood [J].
Baecher-Allan, C ;
Brown, JA ;
Freeman, GJ ;
Hafler, DA .
JOURNAL OF IMMUNOLOGY, 2001, 167 (03) :1245-1253
[5]   Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3 [J].
Chen, WJ ;
Jin, WW ;
Hardegen, N ;
Lei, KJ ;
Li, L ;
Marinos, N ;
McGrady, G ;
Wahl, SM .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 198 (12) :1875-1886
[6]  
Cuenca A, 2003, CANCER RES, V63, P9007
[7]   Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival [J].
Curiel, TJ ;
Coukos, G ;
Zou, LH ;
Alvarez, X ;
Cheng, P ;
Mottram, P ;
Evdemon-Hogan, M ;
Conejo-Garcia, JR ;
Zhang, L ;
Burow, M ;
Zhu, Y ;
Wei, S ;
Kryczek, I ;
Daniel, B ;
Gordon, A ;
Myers, L ;
Lackner, A ;
Disis, ML ;
Knutson, KL ;
Chen, LP ;
Zou, WP .
NATURE MEDICINE, 2004, 10 (09) :942-949
[8]   Human CD4+CD25+ regulatory, contact-dependent T cells induce interleukin 1-producing, contact-independent type 1-like regulatory T cells [J].
Dieckmann, D ;
Bruett, CH ;
Ploettner, H ;
Lutz, MB ;
Schuler, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 196 (02) :247-253
[9]  
FINKE JH, 1993, CANCER RES, V53, P5613
[10]   Foxp3 Programs the Development and Function of CD4+CD25+ Regulatory T Cells (Reprinted from vol 4, pg 330-336, 2003) [J].
Fontenot, Jason D. ;
Gavin, Marc A. ;
Rudensky, Alexander Y. .
JOURNAL OF IMMUNOLOGY, 2017, 198 (03) :986-992